Clinical Trial Update: Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells

View source ↗

Summary

This update describes a long-term follow-up study for participants treated with Kite-sponsored gene-modified cell therapies, with enrollment by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies
• Solid Tumors

Drugs mentioned

• Gene-modified cell therapy (CAR-T)

Snippet

Sponsor: Kite, A Gilead Company | Conditions: Solid and Hematological Malignancies | Status: ENROLLING_BY_INVITATION